We are conducting clinical development of an oral therapeutic cancer vaccine. We have completed a Phase I clinical trial targeting urothelial carcinoma and are currently conducting a Phase I/IIa clinical trial for malignant pleural mesothelioma.
株式会社イムノロック（本社：神戸市、代表取締役CEO：白川利朗、以下「当社」）は、神戸天然物化学株式会社（本社：神戸市、代表取締役社長：真岡宅哉）及び神戸信用金庫（本店：神戸市、代表理事：西多弘行）を...
[画像1: https://prtimes.jp/i/125161/5/resize/d125161-5-29ba4ba02349f2a0e961-2.png ] 株式会社イムノロック（本社：神戸市、代表取締役CEO：白川利朗、以下「当社」）は、株式会社神戸大学キャピタル（KUC1...
[画像1: https://prtimes.jp/i/125161/3/resize/d125161-3-864079061e220d758061-2.png ] 株式会社イムノロック（本社：神戸市、代表取締役CEO：白川利朗、以下「当社」）は、大阪大学ベンチャーキャピタル株式...
株式会社イムノロック（本社：神戸市、代表取締役CEO：白川利朗、以下「当社」）は、下記を引受先とする第三者割当増資を行い、シードラウンドBとして総額1億400万円を2023年7月に調達したことを報告いたします。...
Solaris Bio revolutionizes regenerative medicine by integrating proprietary Animal-Origin-Free (AOF) formulation designs with advanced cell protection expertise. Centered on our "Organic Solvent-Free Cryopreservation Solution," which boasts the highest safety standards, we offer comprehensive cell manufacturing solutions, including world-class growth media. Leveraging innovative R&D and quality verified by the Certificate of Material Eligibility, we simultaneously enhance cell product efficacy and reduce costs, powerfully accelerating the social implementation of next-generation healthcare.
As a drug discovery venture originating from Kyoto University, we are developing RN-501, a novel boron-containing drug for boron-neutron capture therapy (BNCT), a next-generation cancer radiation therapy targeting intractable cancers. Through proprietary boron carbide nanoparticle technology and polyglycerol modification, RN-501 achieves high tumor selectivity and accumulation, along with potent cancer-killing and immune-activating effects with a single intravenous administration, overcoming the limitations of existing drugs. As Japan's first and the world's first nano-BNCT drug, we aim for early societal implementation.
Cells in living organisms function in an orderly manner by cooperating with surrounding cells while interacting with extracellular proteins. However, in cell culture systems, extracellular proteins are largely absent, making it difficult for cells to function properly and often causing them to exhibit physiological activities that differ from those observed in vivo. Our company conducts research on extracellular matrix proteins located outside the cell, and by applying the findings from this research to cell culture technologies, we aim to contribute to the advancement of regenerative medicine and the realization of alternatives to animal experimentation.
Salus Laboratory is a startup company established in January 2022 as a venture originating from Osaka Metropolitan University. Based on research and development of plant-derived functional materials, the company promotes the development and commercialization of multifunctional foods in the health and beauty fields. Guided by scientific evidence, we aim to create products that support cognitive health and extend healthy life expectancy. Our mission is to contribute to healthy longevity by scientifically advancing the concept of “food as medicine.”
